---
layout: default
title: Vincristine
parent: Model Prediction Only (L5)
nav_order: 977
evidence_level: L5
indication_count: 2
monitor_inn: "Vincristine"
predicted_indications: ["vertebral anomalies and variable endocrine and T-cell dysfunction", "retroperitoneal neoplasm"]
last_modified_at: 2026-10-23
description: "Vincristine: predicted new indication Vertebral anomalies and variable endocrine and T-cell dysfunction (evidence level L5). Approved use: Not recorded in the local data"
---

# Vincristine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Vincristine: Vertebral anomalies and variable endocrine and T-cell dysfunction
{: .text-alpha }

## One-Sentence Summary

Vincristine is a vinca alkaloid chemotherapy drug.
The TxGNN model's top-ranked prediction is **vertebral anomalies and variable endocrine and T-cell dysfunction**, a rare congenital syndrome, but **no clinical trials and no publications** support it, so it is a model prediction only.
The second-ranked prediction, **retroperitoneal neoplasm**, has **0 clinical trials** and **20 publications**, mostly case reports and small series in which vincristine was given within multi-drug regimens.

---

## Quick Overview

The table below covers the top-ranked prediction. The second-ranked prediction is discussed in the following sections.

| Item | Content |
|------|------|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Vertebral anomalies and variable endocrine and T-cell dysfunction |
| TxGNN Prediction Score | 0.9924 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (valid licenses: 2 of 2) |
| Number of DINs | 2 (valid: 2) |
| Number of approvals | 2 (both single-ingredient licences) |
| Recommended Decision | Hold |

For the second-ranked prediction, retroperitoneal neoplasm (score 0.9923): no clinical trials, only indirect case-level literature, and a recommendation of "Research Question". Under the evidence rules, no cited study addresses retroperitoneal neoplasm as a disease entity with a defined treatment effect for vincristine, so the evidence level is **L5**, not the L4 shown in the source scoring.

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, vincristine is a vinca alkaloid that binds tubulin, inhibits microtubule assembly and arrests dividing cells in metaphase. This makes it active against rapidly proliferating cells, including lymphoid cells and many tumours.

**Vertebral anomalies and variable endocrine and T-cell dysfunction.** The only loose link is the T-cell component, since vincristine is cytotoxic to lymphoid cells. The condition is a rare congenital developmental and endocrine syndrome, and there is no clear rationale for cytotoxic therapy in it. Any mechanistic argument would be speculative. The high score reflects the model's pattern matching, not demonstrated biology.

**Retroperitoneal neoplasm.** Antimitotic activity is plausible for proliferating tumours. However, "retroperitoneal neoplasm" is a location-based category covering many different tumour types. The supplied literature involves rhabdomyosarcoma, infantile fibrosarcoma, kaposiform hemangioendothelioma, malignant paraganglioma, germ cell tumours and lymphomas that involve the retroperitoneum. Vincristine was always one component of a combination regimen, so its independent contribution cannot be separated.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for either predicted indication.

---

## Literature Evidence

No literature is available for vertebral anomalies and variable endocrine and T-cell dysfunction.

For retroperitoneal neoplasm, the data include 20 publications. Selected entries are below. Key findings are based on the limited abstract text supplied, and no outcome data or study designs were provided beyond what is shown.

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [30054848](https://pubmed.ncbi.nlm.nih.gov/30054848/) | 2018 | Review | World J Pediatr | Review of treatment options for kaposiform hemangioendothelioma in children, with recommendations for future trials |
| [9058098](https://pubmed.ncbi.nlm.nih.gov/9058098/) | 1997 | Case series | Intern Med | Cyclophosphamide, vincristine and dacarbazine used for malignant paraganglioma with retroperitoneal and liver tumours |
| [15739629](https://pubmed.ncbi.nlm.nih.gov/15739629/) | 2004 | Case report / Review | Pediatr Hematol Oncol | Retroperitoneal paraganglioma in a child; chemotherapy debulking with cyclophosphamide, vincristine and dacarbazine may enable surgery |
| [4027886](https://pubmed.ncbi.nlm.nih.gov/4027886/) | 1985 | Case series | Cancer | Two infants with inoperable infantile fibrosarcoma and retroperitoneal involvement achieved complete clinical responses with doxorubicin, vincristine and cyclophosphamide |
| [2191575](https://pubmed.ncbi.nlm.nih.gov/2191575/) | 1990 | Case report | Hinyokika Kiyo | Paratesticular rhabdomyosarcoma with retroperitoneal node metastasis treated with VAC and VAD regimens |
| [2122010](https://pubmed.ncbi.nlm.nih.gov/2122010/) | 1990 | Retrospective series | J Urol | Results of therapy in 18 paratesticular rhabdomyosarcoma cases, including retroperitoneal node dissection and chemotherapy |
| [34689500](https://pubmed.ncbi.nlm.nih.gov/34689500/) | 2021 | Case report | JCPSP | Testicular mixed germ cell tumour with retroperitoneal lymphadenopathy treated with IE and VAC chemotherapy |
| [30652419](https://pubmed.ncbi.nlm.nih.gov/30652419/) | 2019 | Not classified | Cancer Med | Multimodality treatment and risk factors in desmoplastic small round cell tumours |
| [30222020](https://pubmed.ncbi.nlm.nih.gov/30222020/) | 2018 | Case report / Review | J Int Med Res | Interdigitating dendritic cell sarcoma with retroperitoneal involvement treated with a cyclophosphamide, doxorubicin, vincristine and prednisone regimen |
| [2658509](https://pubmed.ncbi.nlm.nih.gov/2658509/) | 1989 | Case report | Hinyokika Kiyo | Advanced paratesticular rhabdomyosarcoma with retroperitoneal metastases |

Some of the 20 supplied publications are only loosely related (for example, a refractory anasarca case and a retroperitoneal infantile haemangioma cohort).

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 02183013 | VINCRISTINE SULFATE INJECTION USP | Not stated | Not stated |
| 02143305 | VINCRISTINE SULFATE INJECTION | Not stated | Not stated |

Both are valid single-ingredient licences. The compiled data contain no approved-indication text, so the approved indications in Canada cannot be stated here. The lymphoid conditions listed above are relations recorded in the knowledge graph, not confirmed approved indications.

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Conventional cytotoxic (vinca alkaloid, antimitotic) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions. The knowledge graph lists leukopenia as a contraindicated condition. |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count, liver function (including bilirubin), and neurological assessment for peripheral neuropathy |
| Handling Protection | Must follow cytotoxic drug handling regulations |

---

## Safety Considerations

- **Contraindication-type relations recorded in the knowledge graph** (not label text): liver failure, hyperbilirubinemia (including Gilbert syndrome), cholestasis (including benign recurrent and familial intrahepatic forms), leukopenia, acute urate nephropathy, peripheral neuropathy and other peripheral nervous system disease (including Charcot-Marie-Tooth disease, motor neuropathy and neuritis), neuromuscular disease, and infectious disease (including fungal infection and dermatophytosis).
- **Drug interactions**: 100 interactions were found. Examples from the first 20 listed:
  - **Major**: clarithromycin.
  - **Moderate**: aprepitant, dexamethasone, metronidazole, eliglustat, naltrexone, glycerol phenylbutyrate, miconazole, rolapitant, rosuvastatin, simvastatin, tinidazole, troglitazone.
  - **Minor**: levofloxacin.
  - **Unknown severity**: calcitriol, pantoprazole, clotrimazole, morphine, metformin, omeprazole.

Label warnings and contraindications from the Health Canada package insert were not available, so please refer to the package insert for authoritative safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The top-ranked prediction has a high model score but no trials, no literature and no plausible mechanistic rationale, so the evidence level is L5.
- The retroperitoneal neoplasm signal comes from case reports and small series in which vincristine was part of multi-drug regimens. It cannot be separated from the other agents, and it also remains L5. It is best treated as a research question, not a basis for a development decision.

**To proceed, the following is needed:**
- The Health Canada package insert, to confirm approved indications, warnings and contraindications
- Detailed mechanism of action data
- For retroperitoneal neoplasm, a defined histology-specific question (for example, a specific sarcoma subtype) with systematic review of vincristine-containing regimens
- Expert review of whether the top-ranked rare syndrome prediction has any biological basis
- A safety monitoring plan covering hepatic impairment, neuropathy, leukopenia and key drug interactions (especially strong CYP3A inhibitors such as clarithromycin)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

